An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole

Archives of Neurology

Volumn 55, Issue 4, 1998, Pages 526-528

  Riviere, Marc ^a   Meininger, Vincent ^b   Zeisser, Phillipe ^c   Munsat, Theodore ^d  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SANOFI   (France)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT OUTCOME;

AMYOTROPHIC LATERAL SCLEROSIS; EXCITATORY AMINO ACID ANTAGONISTS; PROPORTIONAL HAZARDS MODELS; RILUZOLE; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031944832     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.55.4.526     Document Type: Article

References (10)

1. Norris FH, Calanchini PR, Fallat RJ, Panchari S, Jewett B. The administration of guanidine in amyotrophic lateral sclerosis. Neurology. 1974;24:721-725.
2. Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol. 1987;22:328-333.
3. Cedarbaum JM, Charatan M, Stambler N, et al. The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS): prospective validation and changes over time. Neurology. 1993;43(suppl 2):A417. Abstract 9945.
4. Munsat TL, Andres PL, Skerry L. The use of quantitative techniques to define amyotrophic lateral sclerosis. In: Munsat TL, ed. Quantification of Neurological Deficit. Boston, Mass: Butterworths; 1989:129-142.
5. Brooks BR, Lewis D, Rawling J, et al. The natural history of amyotrophic lateral sclerosis. In: Williams AC, ed. Motor Neuron Disease. London, England: Chapman & Hall; 1994:131-169.
6. Cheramy A, Romo R, Barbelto L, Godeheu G, Glowinski J. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett. 1992; 147:209-212.
7. Debono MW, Le Guern J, Canton T, Doble A, Pradier L. Inhibition by riluzole of electrophysiological responses mediated by rate kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol. 1993;235:283-289.
8. Hebert T, Drapeau P, Pradier L, Dunn RJ. Block of the rat brain IIA sodium channel subunit by the neuroprotective drug riluzole. Mol Pharmacol. 1994;45:1055-1060.
9. Bensimon G, Lacomblez L, Meininger V. ALS/Riluzole Study Group: a controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330:585-591.
10. Lacomblex L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347:1425-1431.